Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod.
作者信息
Fragoso Yara Dadalti, Sato Henry Koiti
机构信息
MS Reference Unit, Department of Neurology, Universidade Metropolitana de Santos, Santos, SP, Brazil.
MS Reference Unit, Instituto de Neurologia de Curitiba, Curitiba, PR, Brazil.
出版信息
CNS Neurosci Ther. 2016 Jul;22(7):633-5. doi: 10.1111/cns.12563. Epub 2016 May 3.
Abstract
摘要
相似文献
1
Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod.
CNS Neurosci Ther. 2016 Jul;22(7):633-5. doi: 10.1111/cns.12563. Epub 2016 May 3.
2
[Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
Farm Hosp. 2015 Sep 1;39(5):314-5. doi: 10.7399/fh.2015.39.5.9117.
3
6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis.
J Am Coll Cardiol. 2016 Nov 1;68(18):2027-2029. doi: 10.1016/j.jacc.2016.08.032.
4
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
CNS Drugs. 2018 Jan;32(1):75-84. doi: 10.1007/s40263-017-0482-4.
5
Severe tumefactive rebound of multiple sclerosis following fingolimod cessation.
BMJ Case Rep. 2016 Jun 3;2016:bcr2016215596. doi: 10.1136/bcr-2016-215596.
6
Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
Mult Scler Relat Disord. 2016 May;7:98-101. doi: 10.1016/j.msard.2016.03.017. Epub 2016 Mar 31.
7
Severe fingolimod rebound syndrome after switching to cladribine treatment.
Mult Scler Relat Disord. 2020 May;40:101938. doi: 10.1016/j.msard.2020.101938. Epub 2020 Jan 16.
8
Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
J Clin Neurosci. 2016 Aug;30:166-168. doi: 10.1016/j.jocn.2016.02.003. Epub 2016 Mar 9.
9
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Mult Scler. 2016 Sep;22(10):1315-26. doi: 10.1177/1352458516650736. Epub 2016 May 26.
10
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
CNS Drugs. 2016 Feb;30(2):135-47. doi: 10.1007/s40263-015-0297-0.
引用本文的文献
1
Neurological safety of fingolimod: An updated review.
Clin Exp Neuroimmunol. 2017 Aug;8(3):233-243. doi: 10.1111/cen3.12397. Epub 2017 Jun 18.
2
Redox-based therapeutics in neurodegenerative disease.
Br J Pharmacol. 2017 Jun;174(12):1750-1770. doi: 10.1111/bph.13551. Epub 2016 Aug 25.
本文引用的文献
1
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Mult Scler Relat Disord. 2015 Sep;4(5):400-402. doi: 10.1016/j.msard.2015.05.007. Epub 2015 May 22.
2
Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy.
Acta Neurol Belg. 2016 Mar;116(1):95-7. doi: 10.1007/s13760-015-0495-z. Epub 2015 Jun 14.
3
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
J Neurol Sci. 2014 Sep 15;344(1-2):193-7. doi: 10.1016/j.jns.2014.06.013. Epub 2014 Jun 17.
4
Tumefactive MS lesions under fingolimod: a case report and literature review.
Neurology. 2013 Nov 5;81(19):1654-8. doi: 10.1212/01.wnl.0000435293.34351.11. Epub 2013 Oct 4.
5
Re: Tumefactive multiple sclerosis lesions under fingolimod treatment.
Neurology. 2013 Jul 23;81(4):403. doi: 10.1212/WNL.0b013e31829deeb4.
6
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
J Neurol Sci. 2013 May 15;328(1-2):9-18. doi: 10.1016/j.jns.2013.02.011. Epub 2013 Mar 19.
7
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Mult Scler. 2012 Nov;18(11):1650-2. doi: 10.1177/1352458512463768.
8
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Neurology. 2012 Nov 6;79(19):2000-3. doi: 10.1212/WNL.0b013e3182735cb3. Epub 2012 Oct 3.
9
Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
Neurology. 2009 Mar 17;72(11):1022-4. doi: 10.1212/01.wnl.0000344567.51394.e3.
10
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
Zotero 插件